Showing 3881-3890 of 4063 results for "".
- New President/CEO at The Glaucoma Foundationhttps://modernod.com/news/new-president-ceo-at-the-glaucoma-foundation/2476529/The Board of Directors of The Glaucoma Foundation (TGF) has announced the appointment of Elena Sturman as President and Chief Executive Officer, following the retirement of Scott R. Christensen, who held the position since 2002. She wi
- Jim Wachtman Joins CorneaGen as Chief Commercial Officerhttps://modernod.com/news/jim-wachtman-joins-corneagen-as-chief-commercial-officer/2476527/CorneaGen announced that James “Jim” C. Wachtman has joined the young company as chief commercial officer. Mr. Wachtman has been a leader in the cornea community for 20 years and serves as the chair of the Refractive Surgery Council, a group of industry manufacturers and ophthalmologists focused
- LKC Technologies Launches New UTAS Systems at ARVOhttps://modernod.com/news/lkc-technologies-launches-new-utas-systems-at-arvo/2476520/LKC Technologies has announced the launch of new UTAS systems at the ARVO meeting in Vancouver (booth #1003). The UTAS SunBurst is a small, lightweight and easy to use system capable of conducting full ISCEV-complaint electroretinograms (ERGs), visual evoked potential (VEPs) tests, and ele
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- ImprimisRx to Introduce New Formulations at Cataract & Refractive Surgery Annual Meetinghttps://modernod.com/news/imprimisrx-to-introduce-new-formulations-at-cataract-refractive-surgery-annual-meeting/2476518/ImprimisRx announced its participation at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting to be held at the San Diego Convention Center in San Diego, May 3-7, 2019. At the conference, attendees will have the opportunity to meet with ImprimisRx representative
- Avedro Announces Comprehensive Educational Schedule at ASCRS Annual Meetinghttps://modernod.com/news/avedro-announces-comprehensive-educational-schedule-at-ascrs-annual-meeting/2476513/Avedro announced the inclusion of a wide range of corneal cross-linking and keratoconus scientific and educational programs at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting held M
- Iridex’s MicroPulse Laser Technology Featured in Several Glaucoma and Retina Research Presentationshttps://modernod.com/news/iridexs-micropulse-laser-technology-featured-in-several-glaucoma-and-retina-research-presentations/2476514/Iridex announced that its patented MicroPulse technology played a pivotal role in research presented at the 2019 Association for Research in Vision & Ophthalmology (ARVO) and American Society of Cataract & Refractive Surgeons (ASCRS) meetings, to be held in Vancouver and San Diego, respec
- Bausch + Lomb Announces Update From Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) Studyhttps://modernod.com/news/bausch-lomb-announces-update-from-antibiotic-resistance-monitoring-in-ocular-microorganism-armor-study/2476512/Bausch + Lomb announced the results from nearly 10 years of the ARMOR (Antibiotic Resistance Monitoring in Ocular Microorganisms) surveillance study, presented at the ARVO meeting in Vancouver. Researchers also presented preliminary 2018 surveillance data on antibiotic resistance levels. Initiate
- ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Studyhttps://modernod.com/news/reneuron-announces-presentation-of-updated-efficacy-and-safety-data-from-retinitis-pigmentosa-study/2476502/ReNeuron Group announced updated positive preliminary results in the company’s ongoing phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in retinitis pigmentosa (RP). All three subjects in the first cohort of the phase 2a part of the trial have demonstr
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re